WO2023209650 - METHOD OF DNA PURIFICATION
National phase entry is expected:
Publication Number
WO/2023/209650
Publication Date
02.11.2023
International Application No.
PCT/IB2023/054407
International Filing Date
28.04.2023
Title **
[English]
METHOD OF DNA PURIFICATION
[French]
PROCÉDÉ DE PURIFICATION D'ADN
Applicants **
SEQIRUS INC.
Inventors
LONG, Jacquelyn
Priority Data
63/336,346
29.04.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2364 | |
| EPO | Filing, Examination, Granting | 16455 | |
| Japan | Filing, Examination, Granting | 2483 | |
| South Korea | Filing, Examination, Granting | 2675 | |
| USA | Filing, Examination, Granting | 5110 |
Total:
29,087
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides a method for purifying linear DNA prior to its use to produce RNA, the method comprising ultrafiltering and diafiltering a solution comprising the linear DNA with a membrane having a molecular weight cut off of 200kDa or less. mRNA-based therapies have been shown to be effective in the treatment or prevention of conditions, e.g., in the form of mRNA-based vaccines for the prevention of COVID-19. DNA used in the production of mRNA-based therapies must be sufficiently pure to produce the therapies.[French]
La présente invention concerne un procédé de purification d'ADN linéaire avant son utilisation pour produire de l'ARN, le procédé comprenant l'ultrafiltration et la diafiltration d'une solution comprenant l'ADN linéaire avec une membrane ayant un seuil de coupure moléculaire de 200 kDa ou moins. Des thérapies à base d'ARNm se sont révélées efficaces dans le traitement ou la prévention d'affections, par exemple sous la forme de vaccins à ARNm pour la prévention de la COVID-19. L'ADN utilisé dans la production de thérapies à base d'ARNm doit être suffisamment pur pour produire les thérapies.